IL22 and breast carcinoma: Moreover, IL-22 has been implicated in cancer development and progression (Di Lullo et al., 2015; Hernandez et al., 2018; Keir et al., 2020) including colon cancer (Huber et al., 2012; Kirchberger et al., 2013; Markota et al., 2018; Dmitrieva-Posocco et al., 2019; Arshad et al., 2020) and breast cancer (Kim et al., 2014; Banerjee and Resat, 2016; Irshad et al., 2017; Voigt et al., 2017; Zhang et al., 2020).